Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

10.51 +0.17 (+1.65%)
Delayed Quote Updated: 9:31 AM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
ADMA Biologics (NASDAQ:ADMA) Shares Slide as Q2 Results Miss Estimates ↗
Via Chartmill
News headline image
ADMA Biologics Q2 Earnings Call Highlights ↗
ADMA Biologics (NASDAQ:ADMA) reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. The... 
Via MarketBeat
Topics Earnings
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool
News headline image
3 Biotech Firms With Major Potential Catalysts in the Coming Months ↗
The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms. 
Via MarketBeat
Topics Intellectual Property
ADMA Biologics (NASDAQ:ADMA) Shares Plunge on Q1 Miss and Revenue Guidance Cut ↗
Via Chartmill
ADMA Biologics Inc (NASDAQ:ADMA) Reports Record 2025 Results Driven by ASCENIV, Provides 2026 Outlook ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
ADMA (ADMA) Q1 2026 Earnings Transcript ↗
ADMA (ADMA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Is ADMA Biologics Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Is ADMA Biologics Gaining or Losing Market Support? ↗
 
Via Benzinga
What's going on in today's after hours session ↗
Via Chartmill
News headline image
The Great Rotation of 2026: Why Small Caps are Finally Dethroning the Tech Giants
The financial landscape of 2026 has been defined by a seismic shift in capital allocation that few analysts predicted with such intensity. For the first time in over a decade, the long-dormant Russell... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Why Are Shares Of ADMA Biologics Falling Today? ↗
ADMA Biologics, Inc. (NASDAQ: ADMA) shares are tumbling on Thursday as traders lean into risk-off positioning and punish weaker charts in a down tape. The Nasdaq is down 0.91% while the S&P 500 has... 
Via Benzinga
Topics Stocks
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline. 
Via The Motley Fool
News headline image
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript ↗
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out ↗
This digital banking platform targets U.S. mass market consumers with mobile-first, fee-free services and strategic bank partnerships. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth ↗
Solaris Energy Infrastructure delivers automation and logistics solutions to U.S. oil and gas operators using proprietary technologies. 
Via The Motley Fool
Topics Energy
News headline image
Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗
Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ADMA Biologics Inc (NASDAQ:ADMA) Emerges as a Top GARP Investment Candidate ↗
ADMA Biologics exemplifies GARP investing with strong revenue & earnings growth, high profitability, and a reasonable valuation relative to its biotech peers. 
Via Chartmill
News headline image
This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why ↗
This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why 
Via The Motley Fool
News headline image
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Groupon Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Adma Biologics (ADMA) Q2 Revenue Up 14% ↗
Via The Motley Fool
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.